We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.60 | -0.65% | 91.30 | 91.12 | 91.90 | 92.24 | 91.09 | 91.83 | 891,417 | 16:40:00 |
From Nov 2023 to May 2024
By Dean Seal
Innate Pharma's American depositary receipts rose after the company said Sanofi had exercised its option to license a natural killer cell engager program in solid tumors from Innate's ANKET platform.
The stock was up 14% at $2.79 in premarket trading. Shares had fallen by a third year-to-date when the market closed Monday.
The biopharmaceutical company said early Tuesday morning that the licensing comes pursuant to the terms of a research collaboration and license agreement signed in December 2022.
After a research collaboration period, Sanofi will be responsible for development, manufacturing and commercialization, Innate said, adding that Sanofi still has the option under the license agreement for one additional ANKET target.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 19, 2023 07:13 ET (12:13 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
